Why this matters now The last few decades of biopharmaceutical research have seen an explosion in new therapies, many of which treat illnesses once thought impossible to manage. As innovation continues at an unprecedented pace, life sciences manufacturers are under...
More than 10,000 rare diseases affect over 30 million people in the United States alone, and 95 percent of those diseases have no approved treatment. With more than 1,000 active clinical programs working to change that, the pressure on biopharmaceutical manufacturers to accelerate the pipeline without compromising quality or compliance has never been greater.
As explored in his recent interview in Pharmaceutical Processing World, Emerson’s Bruce Greenwald—drawing on decades of experience—explains that life sciences manufacturers are moving beyond isolated systems toward connected plants to achieve operational excellence...
Life sciences may be the ideal industry for the implementation of AI technologies. After all, bringing a treatment all the way through the drug development process is an extremely complicated undertaking, with tremendous amounts of data and a wide array of...
AI is changing drug discovery faster than most people expected. Commercial manufacturing is next. The organizations best positioned for that shift are the ones preparing now, not because they’re behind, but because the window to prepare thoughtfully is exactly when...
In the Life Sciences industry, accurate measurement is essential to product quality, regulatory compliance, and patient safety. Pharmaceutical manufacturers must regularly calibrate critical instrumentation to meet quality assurance and cGMP requirements, yet extended...
In a recently released BioPhorum paper, BATCH DISPOSITION: A shared vision and practical framework for digitized transformation, Emerson’s Michalle Adkins and Debbie Bouwens joined with other experts in the Life Sciences industry to author this work.
A Genetic Engineering & Biotechnology News article, Beyond Process Development: AI Reshaping Use of Digital Twins, highlights the evolving use of digital twin technology in the Life Sciences industry.
In the last few years, life sciences innovation has jumped by leaps and bounds. Many of the emerging autologous, patient-specific therapies being released are accomplishing things the general public never thought would be possible. These autologous treatments are...
When it comes to process industries, few sectors demand the level of precision and complexity found in pharmaceuticals Imagine the old-fashioned chemical balance in its glass case, a staple of a pharmacist’s bench decades ago, capable of measuring milligrams with...
As technology progresses, it opens up new opportunities for streamlining processes to drive increased reliability and operational excellence. This trend is as true in the life sciences as it is in any other process manufacturing industry. In fact, it might be more...
If there’s one thing that has been repeatedly proven true in the life sciences industry, it’s that automation drives success. After all, automation leads to repeatability, fewer mistakes, higher safety, and faster outcomes. This high success rate for automation in...
We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to stay up to date on the latest news, events and innovations that will help you face and solve your toughest challenges.
Just post a link to the entry and send us a quick note so we can share your work. Thank you very much.
Our Global Community
Emerson Exchange 365
This blog features expert perspectives from Emerson's automation professionals on industry trends, technologies, and best practices. The information shared here is intended to inform and educate our global community of users and partners.